Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ABREVA vs ADEFOVIR DIPIVOXIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits viral DNA polymerase and DNA synthesis of herpes simplex virus (HSV-1 and HSV-2).
Adefovir dipivoxil is a prodrug of adefovir, an acyclic nucleotide analog of adenosine monophosphate. It is phosphorylated intracellularly to adefovir diphosphate, which inhibits hepatitis B virus (HBV) DNA polymerase by competing with the natural substrate deoxyadenosine triphosphate and causing DNA chain termination after incorporation into viral DNA.
Herpes labialis (cold sores) in immunocompetent adults and adolescents ≥12 years
Treatment of chronic hepatitis B in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.,Treatment of chronic hepatitis B in pediatric patients aged 12 years and older.
Apply a thin layer to the affected area 5 times daily for 4 days.
10 mg orally once daily on an empty stomach.
Due to minimal systemic absorption, an elimination half-life cannot be accurately determined in humans. Following intravenous administration in animals, the terminal half-life is approximately 10 hours, but this is not clinically relevant for topical use.
Terminal elimination half-life is 7.5 hours (range 5–10 h); clinically, supports once-daily dosing with dose adjustment for renal impairment.
Docosanol is applied topically with minimal systemic absorption. No significant metabolism occurs. No active metabolites.
Adefovir dipivoxil is rapidly converted to adefovir by esterases. Adefovir is not significantly metabolized; it is eliminated renally by a combination of glomerular filtration and active tubular secretion. No CYP450-mediated metabolism.
Docosanol is minimally absorbed after topical application; systemic absorption is negligible. Any absorbed drug is primarily metabolized and excreted via bile and feces. Renal excretion is insignificant. Less than 1% of the applied dose enters systemic circulation, and nearly all elimination occurs via biliary/fecal routes.
Renal (90% as unchanged drug via active tubular secretion); biliary/fecal (<5%)
Renally negligible; not extensively studied. For the absorbed fraction, protein binding is presumed to be high (>99%) due to the lipophilic nature of docosanol, binding primarily to albumin and lipoproteins.
≤4% (low binding; negligible affinity for serum proteins)
Systemic absorption is minimal; thus Vd is not clinically relevant. Based on animal studies, Vd is estimated to be approximately 1.5 L/kg, reflecting distribution into total body water and lipid compartments.
0.4 L/kg (392 L in adults); indicates extensive tissue distribution (including liver).
Topical administration: bioavailability is less than 1% due to minimal percutaneous absorption; systemic exposure is negligible. Not administered via other routes.
Oral: 59% (range 40–70%); prodrug adefovir dipivoxil is rapidly converted to adefovir.
No dosage adjustment required.
Cr Cl ≥50 m L/min: 10 mg every 24 hours; Cr Cl 30-49 m L/min: 10 mg every 48 hours; Cr Cl 10-29 m L/min: 10 mg every 72 hours; Hemodialysis: 10 mg every 7 days after dialysis.
No dosage adjustment required.
No adjustment required for mild-moderate hepatic impairment (Child-Pugh A or B). Not studied in severe (Child-Pugh C).
Approved for use in patients aged 12 years and older: apply a thin layer 5 times daily for 4 days.
Approved for age ≥12 years: 10 mg orally once daily. For age <12 years, use is not established.
No specific dosage adjustment required; use same as adult dosing.
Monitor renal function; adjust dose based on Cr Cl. No specific dose adjustment solely for age.
None.
WARNING: SEVERE ACUTE EXACERBATION OF HEPATITIS B, NEPHROTOXICITY, HIV RESISTANCE, and LACTIC ACIDOSIS/HEPATOMEGALY WITH STEATOSIS. See full prescribing information for complete boxed warning.
Not for ophthalmic, intranasal, intravaginal, or intraoral use.,Avoid application to mucous membranes.,Immunocompromised patients: consider alternative therapy for severe infections.,Local irritation or allergic contact dermatitis may occur.
Severe acute exacerbation of hepatitis B upon discontinuation of therapy,Nephrotoxicity: monitor renal function, especially in patients at risk or with pre-existing renal impairment,HIV resistance: test for HIV before initiation in patients with unknown HIV status,Lactic acidosis and severe hepatomegaly with steatosis,Use with caution in elderly, renal impairment, or concomitant nephrotoxic agents
Hypersensitivity to docosanol or any component of the formulation.
Hypersensitivity to adefovir dipivoxil or any component of the formulation
No known food interactions. Avoid acidic or spicy foods if they irritate the lesion. Maintain good hydration and nutrition to support immune function.
No clinically significant food interactions; can be taken with or without food. Avoid high-fat meals if gastrointestinal intolerance occurs.
FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk. No adequate human studies in pregnant women. Risk to fetus cannot be ruled out, but potential benefits may warrant use. No first trimester-specific risks identified.
Adefovir dipivoxil is an FDA Pregnancy Category C drug. Animal studies have shown teratogenicity (malformations, embryo-fetal toxicity) at doses 23 times the human therapeutic dose. There are no adequate and well-controlled studies in pregnant women. In first trimester, risk cannot be excluded; use only if benefit outweighs risk. In second and third trimesters, potential for fetal harm exists; consider alternative therapy.
Excretion in human milk unknown. Caution advised. M/P ratio not established.
It is unknown whether adefovir is excreted in human breast milk. Animal studies indicate it is present in rat milk. The M/P ratio is not established. Given the potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during therapy or for 2 weeks after last dose.
No dose adjustment required. Pharmacokinetics not significantly altered in pregnancy.
Pregnancy may increase renal clearance; however, specific pharmacokinetic data are lacking. Dose adjustment is not routinely recommended but may be necessary if renal function changes. Use standard dose of 10 mg once daily with monitoring of renal function and HBV DNA levels.
Apply at first prodromal symptoms (tingling, burning) for maximal efficacy. Avoid application to mucous membranes or inside the nose/mouth. Use a fingertip to apply a thin layer to the lesion; do not share the tube. Lesions should be kept clean and dry; avoid coverings unless instructed. Consider combination therapy with oral antivirals for frequent or severe outbreaks.
Monitor renal function closely; dose adjust for Cr Cl <50 m L/min. Check LFTs and HBV DNA every 3 months. Avoid in decompensated cirrhosis. HIV co-infected patients require concomitant antiretroviral therapy due to risk of HIV resistance. Prolonged therapy may lead to adefovir-resistant HBV mutations (rt A181V/T, rt N236T).
Start applying at the first sign of a cold sore (tingling, itching, or redness).,Wash hands before and after application to prevent spreading the virus.,Apply a small amount (pea-sized) to the affected area, typically 5 times a day until healed.,Do not use on broken skin or mucous membranes (inside mouth, eyes, or genital area).,Avoid kissing or sharing utensils, towels, or lip products while the sore is present.,The tube is for single-patient use only; do not share with others.,May cause mild stinging or redness; if severe irritation occurs, discontinue use.,See a doctor if the sore is severe, lasts longer than 10 days, or you have frequent outbreaks.
Take with or without food at the same time daily.,Do not stop taking without consulting your doctor; stopping may cause severe hepatitis flare.,Report any signs of kidney problems (decreased urination, swelling) or lactic acidosis (unusual muscle pain, trouble breathing).,Regular blood tests are required to monitor liver and kidney function.,Use effective contraception during treatment if you or your partner can become pregnant.,Avoid alcohol and other medications that can damage the liver or kidneys without medical advice.
No interactions on record
"Coadministration of adefovir dipivoxil and tenofovir disoproxil may reduce the antiviral efficacy of tenofovir by competing for renal tubular secretion via organic anion transporters (OATs) and potentially intracellular phosphorylation pathways. This competition can decrease tenofovir's intracellular active metabolite concentrations, leading to suboptimal viral suppression and increased risk of treatment failure in patients with chronic hepatitis B."
"The serum concentration of Teriflunomide can be increased when it is combined with Adefovir dipivoxil."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ABREVA vs ADEFOVIR DIPIVOXIL, answered by our medical review team.
ABREVA is a Antiviral that works by Inhibits viral DNA polymerase and DNA synthesis of herpes simplex virus (HSV-1 and HSV-2).. ADEFOVIR DIPIVOXIL is a Antiviral that works by Adefovir dipivoxil is a prodrug of adefovir, an acyclic nucleotide analog of adenosine monophosphate. It is phosphorylated intracellularly to adefovir diphosphate, which inhibits hepatitis B virus (HBV) DNA polymerase by competing with the natural substrate deoxyadenosine triphosphate and causing DNA chain termination after incorporation into viral DNA.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ABREVA and ADEFOVIR DIPIVOXIL depend on the specific clinical indication. These are both Antiviral agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ABREVA is: Apply a thin layer to the affected area 5 times daily for 4 days.. The standard adult dose of ADEFOVIR DIPIVOXIL is: 10 mg orally once daily on an empty stomach.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ABREVA and ADEFOVIR DIPIVOXIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ABREVA is classified as Category C. FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk. No adequate human studies in pregnant women. Risk to fetus cannot be ruled out, but potential benefits ma. ADEFOVIR DIPIVOXIL is classified as Category C. Adefovir dipivoxil is an FDA Pregnancy Category C drug. Animal studies have shown teratogenicity (malformations, embryo-fetal toxicity) at doses 23 times the human therapeutic dose. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.